Insulet Co. (PODD) Holdings Lifted by Fmr LLC

Fmr LLC boosted its stake in shares of Insulet Co. (NASDAQ:PODD) by 0.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,778,854 shares of the medical instruments supplier’s stock after acquiring an additional 37,973 shares during the quarter. Fmr LLC owned 14.86% of Insulet worth $930,119,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. UBS Group AG boosted its holdings in Insulet by 194.9% in the 1st quarter. UBS Group AG now owns 10,687 shares of the medical instruments supplier’s stock valued at $926,000 after purchasing an additional 7,063 shares during the last quarter. LPL Financial LLC acquired a new position in Insulet in the 1st quarter valued at about $276,000. Principal Financial Group Inc. boosted its holdings in Insulet by 5.8% in the 1st quarter. Principal Financial Group Inc. now owns 37,618 shares of the medical instruments supplier’s stock valued at $3,261,000 after purchasing an additional 2,076 shares during the last quarter. Allianz Asset Management GmbH boosted its holdings in Insulet by 24.4% in the 1st quarter. Allianz Asset Management GmbH now owns 20,749 shares of the medical instruments supplier’s stock valued at $1,798,000 after purchasing an additional 4,074 shares during the last quarter. Finally, State of Alaska Department of Revenue acquired a new position in Insulet in the 2nd quarter valued at about $607,000.

In related news, EVP Aiman Abdel-Malek sold 602 shares of the company’s stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $88.58, for a total transaction of $53,325.16. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Shacey Petrovic sold 960 shares of the company’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $104.26, for a total transaction of $100,089.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,013 shares of company stock worth $856,934. 3.60% of the stock is owned by insiders.

Several equities analysts have weighed in on the stock. Oppenheimer set a $100.00 target price on shares of Insulet and gave the company a “hold” rating in a report on Friday, November 2nd. Morgan Stanley boosted their price target on shares of Insulet from $96.00 to $105.00 and gave the company an “equal weight” rating in a research note on Thursday, October 11th. BidaskClub downgraded shares of Insulet from a “hold” rating to a “sell” rating in a research note on Friday, October 12th. Zacks Investment Research downgraded shares of Insulet from a “buy” rating to a “hold” rating in a research note on Thursday, October 4th. Finally, Leerink Swann reissued an “outperform” rating and issued a $130.00 price target on shares of Insulet in a research note on Tuesday, September 11th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $101.20.

Insulet stock opened at $77.32 on Friday. The company has a market capitalization of $4.61 billion, a PE ratio of -168.09 and a beta of 1.67. Insulet Co. has a 1 year low of $67.43 and a 1 year high of $108.90. The company has a current ratio of 4.58, a quick ratio of 3.99 and a debt-to-equity ratio of 2.95.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, November 1st. The medical instruments supplier reported $0.03 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.01. Insulet had a negative net margin of 2.54% and a negative return on equity of 7.63%. The firm had revenue of $151.10 million for the quarter, compared to the consensus estimate of $148.82 million. During the same period in the prior year, the firm earned ($0.04) EPS. The firm’s revenue for the quarter was up 24.1% on a year-over-year basis. On average, research analysts forecast that Insulet Co. will post -0.05 EPS for the current year.

TRADEMARK VIOLATION WARNING: This article was first reported by WKRB News and is the property of of WKRB News. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.wkrb13.com/2018/11/25/insulet-co-podd-holdings-lifted-by-fmr-llc.html.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

Recommended Story: Short Selling Stocks and Day Traders

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply